Recce Pharmaceuticals Ltd

0
STU:R9Q (Australia)  
€ 0.27 (+7.14%) Nov 5
At Loss
Market Cap:
€ 65.28M ($ 70.39M)
Enterprise V:
€ 63.10M ($ 68.03M)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

Description
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.
Name Current Vs Industry Vs History
Cash-To-Debt 5.44
Equity-to-Asset -1.5
Debt-to-Equity -0.09
Debt-to-EBITDA -0.05
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -3.5
3-Year EPS without NRI Growth Rate -5.2
3-Year FCF Growth Rate -13.2
Name Current Vs Industry Vs History
5-Day RSI 45.11
9-Day RSI 39.44
14-Day RSI 40.15
6-1 Month Momentum % -16.85
12-1 Month Momentum % 22.4

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.34
Quick Ratio 0.34
Cash Ratio 0.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.1
Shareholder Yield % -10.92
Name Current Vs Industry Vs History
ROA % -367.98
ROIC % -1591.82
3-Year ROIIC % -715.14
ROC (Joel Greenblatt) % -2047.17

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -6.18
EV-to-EBITDA -6.31
EV-to-Forward-EBITDA -8.17
EV-to-Forward-Revenue 10.84
EV-to-FCF -7.57
Earnings Yield (Greenblatt) % -16.18
FCF Yield % -12.21

Financials

STU:R9Q's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Recce Pharmaceuticals Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.062
Beta 1.14
Volatility % 70.34
14-Day RSI 40.15
14-Day ATR (€) 0.007434
20-Day SMA (€) 0.2948
12-1 Month Momentum % 22.4
52-Week Range (€) 0.238 - 0.414
Shares Outstanding (Mil) 231.87

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Recce Pharmaceuticals Ltd Filings

Filing Date Document Date Form
No Filing Data

Recce Pharmaceuticals Ltd Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Recce Pharmaceuticals Ltd Frequently Asked Questions

What is Recce Pharmaceuticals Ltd(STU:R9Q)'s stock price today?
The current price of STU:R9Q is €0.27. The 52 week high of STU:R9Q is €0.41 and 52 week low is €0.24.
When is next earnings date of Recce Pharmaceuticals Ltd(STU:R9Q)?
The next earnings date of Recce Pharmaceuticals Ltd(STU:R9Q) is .
Does Recce Pharmaceuticals Ltd(STU:R9Q) pay dividends? If so, how much?
Recce Pharmaceuticals Ltd(STU:R9Q) does not pay dividend.

Press Release

Subject Date
No Press Release